Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Antiviral Res. 2019 Apr 7;167:25–34. doi: 10.1016/j.antiviral.2019.04.004

Figure 3. Prophylactic efficacy of BDGR-69 and -70 tested in C3H/HeN mice and challenged intranasally with VEEV TC-83.

Figure 3.

Groups of six C3H/HeN mice per treatment, vehicle, BDGR-69 or BDGR-70 at 50 mg/kg/day, were assessed for (A) survival and (B) morbidity over 14 days following a s.c. challenge with VEEV TC-83. (C) Treatments were administered i.p. in a volume of 0.1 ml in 21.4% PEG400/8.6% RH40/70% water starting at 2 hours prior to virus infection (D0) and were given BID for 5 days (D0-D4).